PMV Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2013-01-01
- Employees
- 63
- Market Cap
- $81.4M
- Website
- http://www.pmvpharma.com
- Introduction
PMV Pharmaceuticals, Inc. is a precision oncology company, which engages in the discovery and development of small molecule, tumor-agnostic therapies targeting p53. The company was founded by Arnold J. Levine, David Henry Mac, and Thomas E. Shenk in March 2013 and is headquartered in Princeton, NJ.
Clinical Trials
6
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
A Study to Investigate the Effects of Itraconazole on the Pharmacokinetics of PC14586 in Healthy Participants
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- PMV Pharmaceuticals, Inc
- Target Recruit Count
- 12
- Registration Number
- NCT06362642
- Locations
- 🇺🇸
Fortrea, Madison, Wisconsin, United States
A Study to Investigate the Effects of Acid Reducing Agents on Pharmacokinetics of PC14586 in Healthy Participants
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2023-09-26
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- PMV Pharmaceuticals, Inc
- Target Recruit Count
- 28
- Registration Number
- NCT06054464
- Locations
- 🇺🇸
Parexel International, Baltimore, Maryland, United States
AME Study of [14C]-PC14586 in Healthy Male Participants
- Conditions
- Healthy Male Volunteers
- Interventions
- Drug: [14C]-PC14586
- First Posted Date
- 2022-08-31
- Last Posted Date
- 2022-12-20
- Lead Sponsor
- PMV Pharmaceuticals, Inc
- Target Recruit Count
- 8
- Registration Number
- NCT05523687
- Locations
- 🇺🇸
Labcorp Clinical Research Unit Inc., Madison, Wisconsin, United States
Effect of Food on PC14586 in Healthy Volunteers and the PK of PC14586 in Healthy Japanese Volunteers
- First Posted Date
- 2022-02-21
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- PMV Pharmaceuticals, Inc
- Target Recruit Count
- 34
- Registration Number
- NCT05249348
- Locations
- 🇺🇸
Parexel Early Phase Clinical Unit - Los Angeles, Glendale, California, United States
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Conditions
- Advanced Solid TumorAdvanced Malignant NeoplasmMetastatic CancerMetastatic Solid TumorLung CancerOvarian CancerEndometrial CancerProstate CancerColorectal CancerBreast Cancer
- Interventions
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2025-08-06
- Lead Sponsor
- PMV Pharmaceuticals, Inc
- Target Recruit Count
- 230
- Registration Number
- NCT04585750
- Locations
- 🇺🇸
Hoag Cancer Center, Irvine, California, United States
🇺🇸University of California Irvine Chao Family Comprehensive Cancer Center, Irvine, California, United States
🇺🇸UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
News
PMV Pharma's Rezatapopt Shows Promise in TP53-Mutated Solid Tumors and AML/MDS
PMV Pharmaceuticals' PYNNACLE trial advances with Rezatapopt monotherapy for TP53 Y220C mutated solid tumors, showing over 75% site activation across multiple regions.
PMV Pharmaceuticals Provides Update on PC14586 (Rezatapopt) Clinical Trials and Financial Status
PMV Pharmaceuticals is advancing PC14586 (rezatapopt) in a Phase 2 monotherapy trial (PYNNACLE) for solid tumors with p53 Y220C mutations, with interim data expected by mid-2025.
Rezatapopt Shows Promise in Targeting Previously 'Undruggable' p53 Mutation in Advanced Solid Tumors
Rezatapopt, a first-in-class p53 Y220C reactivator, targets the once 'undruggable' p53 Y220C mutation, prevalent in about 1% of all cancers, offering a tumor-agnostic approach.
PMV Pharmaceuticals Reports Promising Clinical Progress and Financial Stability in 2023
PMV Pharmaceuticals reported a net loss of $69.0 million for 2023, an improvement from the previous year, with increased R&D investments focused on advancing rezatapopt.